Conatus

Conatus Global Opens the Door for Lucrative Funding from Top Tier Venture Capitalists

Retrieved on: 
Monday, August 7, 2023
Face, Politics, The Dorchester, Lawyer, Consultant, Karsten, Park Lane, Growth, Conatus

London, United Kingdom--(Newsfile Corp. - August 7, 2023) - Charles Karsten's family-office consortium, Conatus Global, opens doors to deals by bringing startups and investors face to face.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - August 7, 2023) - Charles Karsten's family-office consortium, Conatus Global, opens doors to deals by bringing startups and investors face to face.
  • Two world-renowned venture capitalists recently led a lucrative Series A funding round for a pioneering neuroscience company, brought to their notice through Karsten's offices.
  • Conatus Global will soon host a series of investment events at the prestigious Dorchester Hotel in London's exclusive Park Lane.
  • Such events provide networking opportunities for entrepreneurs and investors unavailable elsewhere and reflect the extraordinary value that working with Conatus Global can offer.

Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension

Retrieved on: 
Thursday, June 1, 2023
Molecular biology, Duke University, BS, University, Senior, Allergy, PAH, Biotechnology, Programming Development Manager, WPP, Strategic planning, Doctor of Philosophy, Bachelor of Science, II, Pain, Inflammation, Syneos Health, MD, Patient, Internal medicine, Fatty liver disease, Biology, Acute respiratory distress syndrome, Hospital, Newcastle University, Pulmonary hypertension, Orthostatic hypertension, ChromeOS, Pharmacology, Conatus, Pfizer, Management, Pharmaceutical industry, New York University

Joshua Ziel, PhD was appointed as Chief Operating Officer and will act as Chief Executive Officer as the company advances AER-901 into Phase 2.

Key Points: 
  • Joshua Ziel, PhD was appointed as Chief Operating Officer and will act as Chief Executive Officer as the company advances AER-901 into Phase 2.
  • Additionally, the company has appointed Gary Burgess, MD, as Chief Medical Officer, and Sarah Fritchley, PhD, as Senior Vice President, Clinical Development and Operations.
  • He joined Aerami in 2022 as Vice President for Program Development with oversight on strategy and execution for the AER-901 pulmonary hypertension program.
  • Dr. Fritchley received her BSc degree in pharmacology from the University of Sheffield, followed by a PhD in immunology from Newcastle University.

Histogen Reports Year-End 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
Methicillin, Trial of the century, IND, Conatus, Acquisition, HST, Medication, Pfizer, Enzyme, ABSSSI, Knee, SAN, Mortgage assumption, Research, NSF, Patient, Extracellular matrix, CCM, Interim, Staphylococcus aureus, EVP, Apoptosis, Cartilage, CSO, Inflammation, COVID-19, Insurance, Caspase, Toxicology, Sale, MRSA, Safety, Pharmaceutical industry, Cryptocurrency, Allergan

Twelve Months Ended December 31, 2022 and 2021

Key Points: 
  • Twelve Months Ended December 31, 2022 and 2021
    For the years ended December 31, 2022 and 2021, we recognized license revenues of $3.8 million and $27 thousand, respectively.
  • For the years ended December 31, 2022 and 2021, we recognized grant revenue of $0 and $0.1 million, respectively.
  • Research and development expenses for the years ended December 31, 2022 and 2021 were $5.0 million and $8.5 million, respectively.
  • General and administrative expenses for the years ended December 31, 2022 and 2021 were $9.4 million and $7.8 million, respectively.

Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

Retrieved on: 
Tuesday, January 3, 2023
Clinical trial, CSO, MIT, Medication, EVP, Pfizer, Rhône-Poulenc, Apoptosis, Conatus, Interim, Yale University, SAN, BS, Acquisition, Biology, Therapy, IND, Worcester Polytechnic Institute, Pharmaceutical industry, Chemistry

“We are very excited about Dr. Spada joining our management team.

Key Points: 
  • “We are very excited about Dr. Spada joining our management team.
  • Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors,” said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief Executive Officer.
  • Prior to joining Aya Biosciences, Dr. Spada was co-founder , EVP of R&D and CSO of Conatus Pharmaceuticals until its merger with Histogen in May 2020.
  • Dr. Spada received his Ph.D. in organic chemistry from MIT and conducted post-doctoral studies at Yale.

HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development

Retrieved on: 
Thursday, October 20, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, San Diego State University, Therapy, T2DM, Business administration, Master of Business Administration, Primary sclerosing cholangitis, Business, Fatty liver disease, Orphan drug, Senior, Partnership, NASH, Ionis Pharmaceuticals, HighTide, Novartis, Apricus Biosciences, CEO, Business development, Fast Track, Conatus, Head, PSC, Solution, Greater China, Program, Pharmaceutical industry, Management, Microbiology

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
  • Mr. Ripley has 25 years of experience in pharmaceutical business development.
  • Prior to Alpha Biopharma, Mr. Ripley served in several senior business development roles.
  • Prior to Conatus, Mr. Ripley was Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals.

Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology Conference

Retrieved on: 
Tuesday, November 2, 2021
Safety, Science, Infection, Immunotherapy, Technology, SAN, Institute of Liver and Biliary Sciences, American College of Allergy, Asthma and Immunology, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, Coronavirus, Private Securities Litigation Reform Act, Lists of diseases, Apoptosis, Conatus, Review, Nature, Conference, LLC, Clinical trial, Intention, CEO, Biomarker, Inflammation, Solution, American College, Immune system, NASH, Cell death, Therapy, Ownership, GLOBE, Asthma, Enzyme, Pharmaceutical industry

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function and its partner, Amerimmune, LLC, today announced that Amerimmune’s CEO, Oral Alpan, MD, will present updated findings from the emricasan Phase 1 study in mild symptomatic COVID-19 patients at the American College of Allergy, Asthma, and Immunology Conference in New Orleans on November 6, 2021. The presentation details are as follows:

Key Points: 
  • Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis.
  • Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.
  • Amerimmune and Histogen reported positive top-line results from its Phase 1 clinical trial in mild COVID-19 patients in June of 2021.
  • Amerimmune LLC is a research center and immunology laboratory with a strong focus on identifying underlying mechanisms of immune disorders.

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

Retrieved on: 
Thursday, May 7, 2020
Elections, Parliamentary procedure, Voting theory, Conatus, Systems theory, Voting, Majority, Articles, Metaphysics, Academic disciplines

The reverse stock split must be approved by a majority of the outstanding shares in order for the merger to close.

Key Points: 
  • The reverse stock split must be approved by a majority of the outstanding shares in order for the merger to close.
  • Conatus announced that over 95% of the votes cast to date have been in favor of the merger with Histogen (Proposal 1).
  • The record date for the special meeting remains March 13, 2020.
  • Voting in favor of Proposal 1 and against Proposal 2 is in effect a no vote for the merger.

Histogen Announces Investigational New Drug Application Amendment for HST 001

Retrieved on: 
Monday, April 6, 2020
Knee cartilage replacement therapy, Conatus

HST 001, or Hair Stimulating Complex (HSC), is designed to be a minimally invasive, physician-administered therapeutic for hair loss.

Key Points: 
  • HST 001, or Hair Stimulating Complex (HSC), is designed to be a minimally invasive, physician-administered therapeutic for hair loss.
  • In addition to clinical development of HST 001, Histogen anticipates IDE and IND filings for its dermal filler (HST 002) and joint cartilage regeneration (HST 003) product candidates in 2020.
  • On January 28, 2020, Histogen announced that it entered into a definitive agreement with Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) pursuant to which Histogen will merge with and into a wholly-owned subsidiary of Conatus in an all-stock transaction.
  • The combined company, led by Histogens current management team, will be named Histogen Inc. and be headquartered in San Diego, CA.